The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.
Order Print Publication
You May Also Be Interested In
This brochure describes the use of methadone in medication-assisted treatment of heroin and other opioids, including narcotic pain medicines. It describes how to use methadone safely, the dangers of methadone overdose, and life-threatening methadone side effects.
This fact sheet describes ways to reduce the risks of taking methadone for pain relief or medication-assisted treatment of opioid use disorders. It lists methadone side effects that require emergency attention and offers resources for additional information.
Advisory: An Introduction to Extended-Release Injectable Naltrexone for the Treatment of People with Opioid Dependence
This advisory gives an overview of extended-release injectable naltrexone for people with opioid dependence. It discusses how it differs from other medication-assisted treatments, safety concerns, and patients most likely to benefit.
Clinical Use of Extended-Release Injectable Naltrexone in the Treatment of Opioid Use Disorder: A Brief Guide
This guide explains how to use extended-release injectable naltrexone as part of medication-assisted treatment (MAT) for opioid use disorder. It covers assessing patients, initiating MAT, monitoring progress, and deciding when to end treatment.
This brochure informs patients about buprenorphine and medication-assisted treatment for opioid use disorder. It describes addiction and withdrawal, how buprenorphine works, its proper use, its side effects, and how it fits with counseling in the recovery process.
This advisory summarizes data on the use of sublingual and transmucosal buprenorphine for the medication-assisted treatment of opioid use disorder.